Pyrosequencing AB:s Patented DNA Sequencing Technology to Assist the National Institutes of Health in Identifying Type 2

Pyrosequencing AB's Patented DNA Sequencing Technology to Assist the National Institutes of Health in Identifying Type 2 Diabetes Gene --Company receives two orders for PSQ@ 96 system-- Uppsala, Sweden, September 11, 2000- Pyrosequencing AB (SSE:PYRO), a devel- oper, manufacturer and marketer of complete systems for applied genetic analy- sis, today reported that the National Institutes of Health's (NIH) National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) has ordered two of the Company's sequencing systems, the PSQ@ 96. The NIDDK will use the Com- pany's Pyrosequencing@ technology to study the relationship between varia- tions, or Single Nucleotide Polymorphisims (SNPs), in genes of diverse patient populations suffering from Type 2 diabetes. "In studies involving Pima Indians, we have identified a region on chromosome 1 that is linked to Type 2 diabetes mellitus. This same genetic region was im- plicated in Type 2 diabetes susceptibility in the Old Order Amish and in Cau- casians living in Utah. Therefore, genes in this region may play an important role in the development of Type 2 diabetes," explained Johanna Wolford, Ph.D., a scientist at the NIH. "It is our hope that we can rapidly sequence the SNPs and candidate genes in this region, and identify genetic mutations associated with Type 2 diabetes." Pyrosequencing's PSQ 96 provides rapid SNP sequencing, and is the first com- mercially available dedicated sequencing-based system for applied genetic analysis. Based on the Company's patented Pyrosequencing@ technology, the product provides rapid and accurate genetic analysis and offers a high capac- ity, cost-effective solution for SNP analysis and Tag sequencing- the analysis of short DNA sequences used for genetic identification. PSQ 96 Systems, launched earlier this year, include a sequencing instrument, software, and reagent kits necessary to conduct SNP analysis. "We are excited that the NIDDK has selected our technology to carry out this important work," said Erik Walldén, President and CEO of Pyrosequencing AB. "There are several technologies available to perform SNP analysis, and we are gratified that the PSQ 96 System was judged as the one that has the best in- ternal quality control, automated processing capabilities, as well as the most user-friendly system for applied genetic analysis." The NIDDK conducts and supports research on many of the most serious diseases affecting public health. The Institute supports much of the clinical research on the diseases of internal medicine and related subspecialty fields as well as many basic science disciplines. The Institute supports basic and clinical research through investigator-initiated grants, program projects and center grants and career development training awards. The Institute also supports re- search and development projects and large-scale clinical trials through con- tracts. About Pyrosequencing AB Pyrosequencing AB develops, manufactures and markets complete systems for ap- plied genetic analysis based on its proprietary Pyrosequencing@ technology. Applied genetic analysis may be used for drug development, drug selection and diagnostics. Pyrosequencing's technology addresses the increasing demand for applied genetic analysis across various markets, including research and clini- cal routine testing and large-scale customized industrial applications such as drug development by pharmaceutical companies. The Company is headquartered in Uppsala, Sweden with a North American subsidiary, Pyrosequencing, Inc., lo- cated in Westborough, MA. Pyrosequencing AB also has sales offices and distri- bution partners in Scandinavia, United Kingdom, Germany, BeNeLux, Switzerland and Japan. Pyrosequencing AB is listed on the OM Stockholm Exchange, under the ticker "PYRO". Pyrosequencing's Web site address is Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Pyrosequencing's current expectations. The Private Securities Litigation Re- form Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Pyrosequencing notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and ge- nomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Pyrosequencing's products (includ- ing seasonal fluctuations), difficulties in successfully adapting the Com- pany's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors. FOR FURTHER INFORMATION CONTACT: Pyrosequencing AB Media Erik Walldén Sören Densjö President & CEO Densjö Communications AB E-MAIL E-MAIL: Phone: +46 18 565902 or 070-326 98 70 Phone: +46 70 585 0525 Harry Wilcox Fredda Malkoff Executive VP, Chief of Finance & Corporate Development Feinstein Kean Healthcare E-MAIL: E-MAIL: Phone: +1 508 389 9911 ext. 120 Phone: +1 617-761-6747 ------------------------------------------------------------ This information was brought to you by BIT The following files are available for download: